<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231212060345N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-04</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effect of vascular stromal cells and platelet-rich plasma in the treatment of osteochondral lesions of the talus</public_title>
      <acronym></acronym>
      <scientific_title>Therapeutic impact of Adipose-derived Stromal Vascular Fraction And Platelet-rich plasma on non-operative treatment of osteochondral lesions of the talus: A Randomized Controlled Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74340</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization method is simple, the randomization is individual, there is no stratified randomization, randomization with the NIH site tool, and the final Excel is prepared for randomization. Is.
After entering the study according to the conditions mainly mentioned above, it is determined what intervention is performed for each patient based on a predetermined chain in Excel. For example, row 1 T is equivalent to the intervention group or row 2 C is equivalent to the control group.
The patients are chained according to the order of referral, the first patient in the first row, the second patient in the second row, and so on.</study_design>
      <phase>N/A</phase>
      <hc_freetext>talus osteochondral lesions- talus osteochondritis dissecans.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: intra-articular injection of vascular stromal cells taken from fat, necessary equipment, svf extraction kit-syringe, SVF preparation: about 100 mL of adipose tissue is taken sterilely through liposuction of the abdomen. The obtained fat will be emulsified by passing through 2.4 mm, 1.2 mm filters and finally a 400 and 600 micrometer filter (25-30 passes). In order to separate free fatty acids, these nanofats are centrifuged (for 2 minutes at 1200 rpm) and the separated fatty acids will be discarded. The number of cells in the remaining substance will be counted under the microscope. The obtained nanofat is prepared for injection into the joint. The injection volume is 4-5 cc. The quantity and viability of the cells is done through direct observation under the neobar slide. After the injection, the patient must not apply weight for 24 hours The leg should be restrained (walk with a cane) and only paracetamol is allowed to be used for pain control. After a week, the patients will be contacted and questions will be asked about possible side effects. Intervention 2: Control group: Intervention group: intra-articular injection of platelet-rich plasma taken from peripheral blood, necessary equipment for PRP extraction kit-syringe, first blood is taken from a peripheral vein, then PRP is extracted from it with a centrifuge and injected for one time after injecting the patient until For 24 hours, he must refrain from putting weight on his leg (walk with a cane) and to control pain, only paracetamol is allowed to be used. After one week, patients will be contacted and questions will be asked about possible side effects.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Agree with the study team</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sina Hajiaghajani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 9 , Abdollahi ally, Darabad square , Poorebtehaj street, Ajoodanieh street, Aghdasieh</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1956854733</zip>
        <telephone>+98 21 2610 6712</telephone>
        <email>sinaaghajani1379@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sina Hajiaghajani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 9 , Abdollahi ally, Darabad square , Poorebtehaj street, Ajoodanieh street, Aghdasieh</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1956854733</zip>
        <telephone>+98 21 2610 6712</telephone>
        <email>sinaaghajani1379@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The symptoms have been continuous for at least 3 months and have not responded to conservative treatment
age 18-70 years
Patients with grade I, II Bernadet and Harry classification lesions
CT SCAN and MRI confirm the diagnosis and no other pathology is involved
The patient has the ability to understand the explanations and registers her verbal and written wishes in the informed consent form</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>presence of inflammatory arthritis such as rheumatoid arthritis, other systemic diseases such as diabetes and systemic inflammatory diseases; Systemic infection
History of cardiovascular disease such as previous stroke or heart failure or coagulation problem such as disturbed PT, PTT, INR
Any surgery or intra-articular injection
Drug users or alcoholics
Pregnancy or breastfeeding
Severe weight loss in such a way that liposuction is not possible.
Abdominal hernia
The presence of loose bodies, osteoarthritic changes, impingement spurs, or other pathology</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M93.27</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteochondritis dissecans of ankle and joints of foot</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: intra-articular injection of vascular stromal cells taken from fat, necessary equipment, svf extraction kit-syringe, SVF preparation: about 100 mL of adipose tissue is taken sterilely through liposuction of the abdomen. The obtained fat will be emulsified by passing through 2.4 mm, 1.2 mm filters and finally a 400 and 600 micrometer filter (25-30 passes). In order to separate free fatty acids, these nanofats are centrifuged (for 2 minutes at 1200 rpm) and the separated fatty acids will be discarded. The number of cells in the remaining substance will be counted under the microscope. The obtained nanofat is prepared for injection into the joint. The injection volume is 4-5 cc. The quantity and viability of the cells is done through direct observation under the neobar slide. After the injection, the patient must not apply weight for 24 hours The leg should be restrained (walk with a cane) and only paracetamol is allowed to be used for pain control. After a week, the patients will be contacted and questions will be asked about possible side effects.</i_keyword>
      <i_keyword>Control group: Intervention group: intra-articular injection of platelet-rich plasma taken from peripheral blood, necessary equipment for PRP extraction kit-syringe, first blood is taken from a peripheral vein, then PRP is extracted from it with a centrifuge and injected for one time after injecting the patient until For 24 hours, he must refrain from putting weight on his leg (walk with a cane) and to control pain, only paracetamol is allowed to be used. After one week, patients will be contacted and questions will be asked about possible side effects.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Diameter of Lesion. Timepoint: before entering the study -  six months later. Method of measurement: CT scan.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Function of ankle. Timepoint: before entering the study - one month later - three months later - six months later. Method of measurement: American Orthopedic Foot and Ankle Society questionnaire.</sec_outcome>
      <sec_outcome>Pain. Timepoint: before entering the study - one month later - three months later - six months later. Method of measurement: visual analog scale.</sec_outcome>
      <sec_outcome>Osteoarthritis changes. Timepoint: before entering the study - one month later - three months later - six months later. Method of measurement: Ankle osteoarthritis scale questionnaire.</sec_outcome>
      <sec_outcome>Lesion grade. Timepoint: before entering the study - six months later. Method of measurement: CT scan - Berndet and harty classification.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-11-01</approval_date>
        <contact_name>Working Group/Committee of Research Ethics of Dermatology Research Center - Shahid Beheshti Universi</contact_name>
        <contact_address>Tehran - Quds town (west) - between South Flamak and Zarafshan, Simai Iran St. - Central Headquarters of Ministry of Health, Treatment and Medical Education, Block A, 13th floor tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
